[PRACTICE NOTE] Pharma's Consumer-Grade Imperative: Closing the Symmetry Gap
Most organizations hold themselves to more than one standard without ever deciding to. One standard governs the thing they sell, written down, measured, audited and defended in front of regulators. The other governs everything that happens around the thing they sell, and it tends to be inherited rather than designed.
In pharmaceuticals the distance between those two standards is unusually wide. The product is engineered to a tolerance almost no other industry can approach. The brand that carries it is designed with similar deliberation, while the experience surrounding both is largely left to default. I have come to call that distance the symmetry gap, and closing it is commercial work rather than service work.
Two standards inside one company
The gap rarely comes from indifference. An organization that can hold a molecule to microgram tolerances is not a careless organization. The engineered standard simply stops at the edge of the plant, where ownership becomes shared and no single function answers for the whole. What follows is variation, and variation is what a customer reads as the real standard.
Deloitte's work on engagement in pharma puts numbers against that asymmetry. It reports that only 28% of HCPs believe pharma's customer engagement strategies meet their needs, while 82% of life sciences executives say they are satisfied with those same strategies. Those two figures describe two different companies. Internal confidence tends to track intent, while customer judgment tracks delivery.
Field teams, medical teams and hub staff deserve respect in this argument. They are often producing acceptable outcomes by absorbing the defects of a process that was never built to carry what it is asked to carry. Heroics of that kind can hold a system together for years. They also hide the design problem from the people who could fund the repair.
What Consumer-Grade actually means
Consumer-Grade is a standard rather than an aspiration. It does not ask a manufacturer to become Amazon or Apple, and it does not ask science to behave like retail. It means the bar a patient applies has already been set somewhere else. She does not reset that bar when she becomes a patient.
Consider an ordinary Tuesday in her life. She tracked a parcel to the minute this morning. She changed a flight on a phone in ninety seconds. She then called a manufacturer's hub and repeated a date of birth four times. She is comparing the company to the last competent transaction she had rather than to another pharmaceutical company.
None of this concerns conviction. Pharmaceutical companies are patient-centric by nature, and the people inside them have rarely needed persuading to care about patients. What has changed is the arena. These companies are now operating in a consumer arena where people have choice, and Consumer-Grade is a capability to be designed in rather than a conviction to be held.
The specification behind the standard
A standard that cannot be specified is a mood, and a mood cannot be governed. The Consumer-Grade Specification is a closed structural set of six conditions: Recognition, Anticipation, Coherence, Effort, Resolution and Visibility. Each one can be observed in an interaction and each one can carry a threshold. Thresholds are set per organization, because what counts as acceptable effort in a rare disease journey differs from what counts in primary care.
Consider a single hub interaction read against those conditions. Recognition means the patient is known on the second call, and Anticipation means the prior authorization is raised before she thinks to ask. Coherence holds context across handoffs, Effort removes the repeated data capture, and Resolution closes the matter without a second attempt. Visibility means she can see where things stand without calling to find out.
Felt attributes are where most conversations about experience stall. Easy, simple, fast and transparent are reported outcomes rather than design inputs, which is why instructing an organization to be easier rarely changes anything. Those attributes decompose into the six conditions, and the conditions are what a company can actually build, measure and govern. Specified this way, experience becomes auditable in the way manufacturing variance is auditable.
Positivity bias quietly flattens a differentiated portfolio
Customers often find it difficult to separate their perceptions of one company from the next. They are left with the impression that all the companies involved in a decision are generally positive and generally the same. In my book I described that cognitive effect as the thing that marginalizes, homogenizes and commoditizes value propositions. It works behind expensive brand investment, and it rarely announces itself in a tracking study.
In a therapeutic category where clinical profiles converge, that effect becomes a strategic problem rather than a branding one. Two agents with comparable data and comparable labels can collapse into one impression of general adequacy. What survives that collapse is usually experiential. Bain's work on commercial productivity found that about 40% of a doctor's drug recommendations relate to their overall experience with the company rather than the product alone.
Experiential factors have become the basis of competition
Customers now carry the same expectation into every interaction regardless of category. Whether they are applying for a mortgage, grocery shopping or working through any of the other jobs of daily life, they anticipate a similar level of convenience and care. The outlier companies that set that expectation rarely sit inside the industry being judged against it. Experiential factors such as helpfulness, consistency, simplicity, personalization and transparency have become the live terrain of competition.
My book describes this shift as Experiential Commerce, and it changes where exchanged value actually sits. Value moves from the functional utility of the offering toward the intangible factors that surround it. For a commercial organization that does not control the transaction between its science and a patient, the implication can be uncomfortable. Much of what determines perceived value happens in places the commercial model does not currently instrument.
The window for getting this right is also narrowing. Veeva's research shows that 45% of HCPs are accessible to biopharma companies, down from 60% eighteen months earlier. Fewer chances to be seen means each remaining interaction carries more weight than it did, so variability stops being a service irritation and becomes a risk to preference.
Regulation governs claims rather than burden
The industry's reflex when a Consumer-Grade standard is raised is to point at regulation. That reflex deserves to be taken seriously, because the constraints are real and the penalties are not theoretical. Regulation here governs claims. It does not govern burden.
Almost none of the friction a patient meets between a prescription and a first dose is legally required. The repeated data capture, the unexplained wait and the handoff that drops context are artifacts of how work was divided internally. That friction is unowned rather than mandated, which is what makes the gap available to close. In regulated industries the assumed constraint and the actual constraint are often treated as the same thing.
Importing consumer practice wholesale will not close it either. The first iterations of customer experience brought into pharma did not fit the industry. The clinical workflow, the payer, the pharmacy and the hub all sit between a company and the outcome it needs. The rejection that followed was rational, and the wrong lesson was drawn from it. Consumer experience models rarely transfer into pharma intact, which argues for a pharma-specific interpretation rather than for abandoning the standard.
The arithmetic of leaving the gap open
Experience is the third leg of the value proposition alongside product and brand, and it is the leg most often left to default. A company can engineer a molecule and build a brand with equal discipline and still watch earned value decay in the space between them. That decay has a name and a measure. The share of earned value that becomes sustained therapy is the Realization Rate, and the distance between earned and realized value is value leakage.
In work published with TheyDo I traced an illustrative compounded scenario through that distance. A billion dollars of earned value becomes roughly seven hundred million after prescriptions that are never filled. It falls again after early discontinuation, and settles near four hundred and fifty million in realized value once long term adherence erosion is counted. The ladder is an illustration rather than a benchmark, and no competitor takes the difference.
Value that leaks in this way looks like nothing on a scorecard. There is no lost bid, no competitive switch and no line item that names the cause. The friction is distributed across thousands of small interactions, each one too minor to escalate on its own. Nothing in the reporting line is built to add them up. That is the accounting signature of an experience left to default.
Where the work begins
Closing the gap starts with naming the system that owns it. The commercial model ends at the written prescription, while value realization runs across the Path to Prescribe, the Path to Fulfill and the Path to Adhere. Very little in the current operating model answers for progression across all three. Ownership of the whole is what has been missing, not effort.
That ownership is the fourth domain of commercial excellence, sitting alongside launch excellence, marketing excellence and sales excellence. Customer Excellence is the missing domain, and it behaves like a quality system rather than a sentiment program. Defining the six conditions as a specification, measuring variation against them and governing the result with the seriousness given to manufacturing variance is the practical path. The symmetry gap closes when the standard outside the plant is written down as carefully as the one inside it.
Key Takeaways
- The symmetry gap is the distance between the standard a company applies to its product and the standard it applies to everything around the product.
- Consumer-Grade is a standard rather than an aspiration, because the bar a patient applies was set by the last competent transaction she had in any category.
- The Consumer-Grade Specification is a closed structural set of six conditions, Recognition, Anticipation, Coherence, Effort, Resolution and Visibility, with thresholds set per organization.
- Felt attributes such as easy, simple, fast and transparent are reported outcomes that decompose into those six conditions rather than things a company can build directly.
- Regulation governs claims rather than burden, so most of the friction between a prescription and a first dose is unowned rather than mandated.
- Leaving the gap open shows up as value leakage and a depressed Realization Rate rather than as a competitive loss anyone can point to.
Diagnostic Questions to Consider
- Name the experiential standard the commercial organization is held to, and say where it is written down.
- Score one high volume interaction against Recognition, Anticipation, Coherence, Effort, Resolution and Visibility, and state the threshold for each.
- Separate the friction between prescription and first dose into what regulation actually requires and what the operating model merely inherited.
- State who answers for progression across the Path to Prescribe, the Path to Fulfill and the Path to Adhere as one system.
- Estimate the share of earned value that becomes sustained therapy, and say what that Realization Rate would need to be for the gap to stop mattering.
Closing Reflection
The companies that close this gap will not do it by caring more, because the caring was never in short supply. They will do it by extending an engineering instinct they already have into territory where it was never applied. Pharma knows how to specify a standard, observe deviation from it and govern the result, because that discipline built the product in the first place. The work is to point that same instinct at the experience surrounding the molecule.
What makes the symmetry gap worth leadership attention is that no one else can take the value it destroys. A competitor cannot capture a prescription abandoned at a prior authorization or a therapy discontinued in week three. That value simply leaves the system, and it leaves quietly enough that the commercial organization may never see it go. Science earns the right to be considered, while experience largely decides whether that right is realized.
About the Author
Wayne Simmons is the founder of The Customer Excellence AGENCY and the author of The Customer Excellence Enterprise (Wiley, 2024). He is founding faculty of the MS in Customer Experience Management at Michigan State University's Broad College of Business. He led global customer excellence in Pfizer's first Chief Marketing Organization and in Bayer's Customer Powerhouse.
The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.
